Cargando…

Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma

The Golgi apparatus (GA) is a cellular organelle that participates in the packaging, modification, and transport of proteins and lipids from the endoplasmic reticulum to be further fabricated before being presented to other cellular components. Recent studies have demonstrated that GA facilitates nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yupeng, Ouyang, Wenhao, Zhang, Chenzi, Yu, Yunfang, Yao, Herui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811463/
https://www.ncbi.nlm.nih.gov/pubmed/35127727
http://dx.doi.org/10.3389/fcell.2021.817085
_version_ 1784644442036109312
author Jiang, Yupeng
Ouyang, Wenhao
Zhang, Chenzi
Yu, Yunfang
Yao, Herui
author_facet Jiang, Yupeng
Ouyang, Wenhao
Zhang, Chenzi
Yu, Yunfang
Yao, Herui
author_sort Jiang, Yupeng
collection PubMed
description The Golgi apparatus (GA) is a cellular organelle that participates in the packaging, modification, and transport of proteins and lipids from the endoplasmic reticulum to be further fabricated before being presented to other cellular components. Recent studies have demonstrated that GA facilitates numerous cellular processes in cancer development. Therefore, this study aimed to establish a novel lung adenocarcinoma (LUAD) risk evaluation model based on GA gene signatures. In this study, we used TCGA-LUAD (n = 500) as the training cohort and GSE50081 (n = 127), GSE68465 (442), and GSE72094 (398) as the validation cohorts. Two immunotherapy datasets (GSE135222 and GSE126044) were also obtained from a previous study. Based on machine algorithms and bioinformatics methods, a GA gene-related risk score (GARS) was established. We found that the GARS independently predicted the prognosis of LUAD patients and remained effective across stages IA to IIIA. Then, we identified that the GARS was highly correlated with mutations in P53 and TTN. Further, this study identified that GARS is related to multiple immune microenvironmental characteristics. Furthermore, we investigated GSE135222 and GSE126044 and found that a lower GARS may be indicative of an improved therapeutic effect of PD-1/PD-L1 therapy. We also found that high GARS may lead to a better response to multiple anticancer drugs. Finally, we established a nomogram to better guide clinical application. To our knowledge, this is the first study to demonstrate a novel GA signature-based risk score formula to predict clinical prognosis and guide the treatment of LUAD patients.
format Online
Article
Text
id pubmed-8811463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88114632022-02-04 Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma Jiang, Yupeng Ouyang, Wenhao Zhang, Chenzi Yu, Yunfang Yao, Herui Front Cell Dev Biol Cell and Developmental Biology The Golgi apparatus (GA) is a cellular organelle that participates in the packaging, modification, and transport of proteins and lipids from the endoplasmic reticulum to be further fabricated before being presented to other cellular components. Recent studies have demonstrated that GA facilitates numerous cellular processes in cancer development. Therefore, this study aimed to establish a novel lung adenocarcinoma (LUAD) risk evaluation model based on GA gene signatures. In this study, we used TCGA-LUAD (n = 500) as the training cohort and GSE50081 (n = 127), GSE68465 (442), and GSE72094 (398) as the validation cohorts. Two immunotherapy datasets (GSE135222 and GSE126044) were also obtained from a previous study. Based on machine algorithms and bioinformatics methods, a GA gene-related risk score (GARS) was established. We found that the GARS independently predicted the prognosis of LUAD patients and remained effective across stages IA to IIIA. Then, we identified that the GARS was highly correlated with mutations in P53 and TTN. Further, this study identified that GARS is related to multiple immune microenvironmental characteristics. Furthermore, we investigated GSE135222 and GSE126044 and found that a lower GARS may be indicative of an improved therapeutic effect of PD-1/PD-L1 therapy. We also found that high GARS may lead to a better response to multiple anticancer drugs. Finally, we established a nomogram to better guide clinical application. To our knowledge, this is the first study to demonstrate a novel GA signature-based risk score formula to predict clinical prognosis and guide the treatment of LUAD patients. Frontiers Media S.A. 2022-01-20 /pmc/articles/PMC8811463/ /pubmed/35127727 http://dx.doi.org/10.3389/fcell.2021.817085 Text en Copyright © 2022 Jiang, Ouyang, Zhang, Yu and Yao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Jiang, Yupeng
Ouyang, Wenhao
Zhang, Chenzi
Yu, Yunfang
Yao, Herui
Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title_full Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title_fullStr Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title_full_unstemmed Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title_short Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma
title_sort prognosis and immunotherapy response with a novel golgi apparatus signature-based formula in lung adenocarcinoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811463/
https://www.ncbi.nlm.nih.gov/pubmed/35127727
http://dx.doi.org/10.3389/fcell.2021.817085
work_keys_str_mv AT jiangyupeng prognosisandimmunotherapyresponsewithanovelgolgiapparatussignaturebasedformulainlungadenocarcinoma
AT ouyangwenhao prognosisandimmunotherapyresponsewithanovelgolgiapparatussignaturebasedformulainlungadenocarcinoma
AT zhangchenzi prognosisandimmunotherapyresponsewithanovelgolgiapparatussignaturebasedformulainlungadenocarcinoma
AT yuyunfang prognosisandimmunotherapyresponsewithanovelgolgiapparatussignaturebasedformulainlungadenocarcinoma
AT yaoherui prognosisandimmunotherapyresponsewithanovelgolgiapparatussignaturebasedformulainlungadenocarcinoma